Aprogen

Overview
Biosimilars?
Product stageSegments
Early
?
Diversified Drug Developers
?

Aprogen is a biotechnology company based in Seongnam-Si, South Korea, focusing on delivering innovative and cost-effective solutions to patients. Founded in 2000 by Jaeseob Kim, the company specializes in developing biosimilars, which are biologic medical products highly similar to original products but manufactured by different companies after the original product's patent expires. Aprogen's flagship product is a Remicade biosimilar used to treat autoimmune diseases such as rheumatoid arthritis and Crohn's disease. The company's expertise in biosimilar development has earned it the title of "the second Celltrion," referring to another prominent South Korean biopharmaceutical company. In May 2019, Aprogen's valuation surpassed 1 trillion won (approximately USD 836 million), granting it unicorn status and making it the first Korean biotech startup to achieve this milestone. As of 2023, Aprogen continues to operate in the biotechnology sector, with the South Korean government recognizing the industry's potential as a new growth engine for the country's economy.

Key customers and partnerships

Aprogen has attracted investments from notable entities in the pharmaceutical and investment sectors. In May 2019, the company received a 20 billion won (USD 16.7 million) investment from Lindeman Asia Investment, which played a crucial role in elevating its valuation to unicorn status. Additionally, Nichi-lko Pharmaceutical has been identified as another investor in the company.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
Dungchon-dong 545 B1, Jungwon-gu Seongnam KOR
Founded year:
2000
Employees:
11-50
IPO status:
Unknown
Total funding:
USD 17.2 mn
Last Funding:
-
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.